Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

This Sources Sought opportunity from Department Of Veterans Affairs was posted on June 10, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

6505--Request for Infromation - U.S. Produced Pharmaceuticals

Closed
36E79726Q0002Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The U.S. Department of Veterans Affairs is conducting market research through a Request for Information to identify potential sources of U.S.-produced pharmaceuticals in alignment with Executive Order 13944, which emphasizes securing domestic supply chains for essential medicines and medical countermeasures. The VA seeks information on pharmaceuticals that meet the strict definition of U.S.-produced: where critical inputs are manufactured in the United States and the finished drug product is fully manufactured, prepared, propagated, compounded, or processed within the U.S. as defined by federal law. The request specifically targets products listed in Attachment 1, including high-volume injectables such as Dexamethasone Sodium Phosphate, Fentanyl Citrate, Heparin Sodium, and Hydromorphone HCI, with estimated annual quantities provided for market assessment. Respondents must disclose the country of origin for all ingredients and components to allow validation of compliance with EO 13944, and are encouraged to indicate any domestic manufacturing activity, even if not fully U.S.-produced, as such contributions are still of significant value to the VA’s supply resilience goals. All responses must be submitted via a provided spreadsheet with detailed comments on product availability and market conditions, and must include a unique eleven-digit NDC number with the labeler code identifying the respondent as the official labeler, ensuring no labeling conflicts or over-labeling occurs. The VA intends for any resulting contract to have a one-year base period with four one-year option periods to ensure long-term consistency of supply. To qualify, respondents must confirm they have or can obtain a unique NDC for each product and either manufacture the product themselves or provide a binding letter of commitment from the manufacturer guaranteeing supply sufficient to meet government needs, including maintaining at least six months of stock per product. Contractors must also have active chargeback agreements in place with the Pharmaceutical Prime Vendor Program, which handles all VA and Department of Defense pharmaceutical procurement. Companies must indicate their size under NAICS code 325412 and, if small, whether they perform at least 50% of the manufacturing processes. Responses must be submitted by June 24, 2026, and must confirm the ability to begin delivery within 60 days of contract award. This RFI is for planning purposes only and does not constitute a solicitation or guarantee of future procurement, but serves to shape potential future acquisition strategies aimed at reducing supply chain vulnerabilities and ensuring reliable access to critical medications for veterans.

General Info

VA seeks US-made pharmaceuticals info to strengthen supply chains, ensure compliance, and inform contracts.

Agency

Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)View Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

IL

Set-Aside

NONE

Documents

(2)

RFI 36E79726Q0002 - U.S. Produced Pharmaceuticals

DOCXrfi

VA Pharmaceutical Product List

XLSXproduct-list

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Sources Sought

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)
Contacts1 person available
OfficeHINES, IL, 60141, USA
Organization / Agency
Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)
View Agency Profile
Office AddressHINES, IL, 60141, USA
Contacts
Nicholas McGregorContracting Officer

Full Description

Show more
REQUEST FOR INFORMATION Page 4 of 4 U.S. Department of Veterans Affairs
U.S. Produced Pharmaceuticals
Request for Information
Company Name: _________________________
Pursuant to Executive Order (EO) 13944, the Department of Veterans Affairs (VA) is conducting market research to identify sources of U.S. Produced Pharmaceuticals. At this time, VA is seeking to collect information. There is no guarantee that a solicitation will be issued or that any future solicitation would include all of the products attached to this questionnaire. VA understands that many pharmaceuticals rely on ingredients from all over the world. While worldwide supply chains create cost efficiencies, they create potential vulnerabilities and disruptions for the U.S. supply chain, which can put patient safety at risk. This market research seeks information necessary to assess whether procurement opportunities for U.S. produced pharmaceuticals exist that can mitigate these risks. VA s highest priority is identifying pharmaceuticals that fully qualify as U.S.-Produced under EO 13944; however, VA also places significant value on products that incorporate any U.S. manufacturing activity, including domestic production of critical inputs, intermediate steps, or final processing. Specifically, VA is seeking to identify pharmaceuticals that are produced in the U.S., as defined in EO 13944 (August 6, 2020)
An Essential Medicine or Medical Countermeasure is produced in the United States if the Critical Inputs used to produce the Essential Medicine or Medical Countermeasures are produced in the United States and if the Finished Drug Product or Finished Device, are manufactured, prepared, propagated, compounded, or processed, as those terms are defined in section 360(a)(1) of title 21, United States Code, in the United States. Exec. Order No. 13944, 85 FR 49929, 49933 (August 6, 2020) Pharmaceuticals of particular interest are listed on Attachment 1.
Please complete all columns in yellow. For the columns requesting the origin of various ingredients and components, please indicate the origin country. This information will allow VA to verify whether the pharmaceutical is wholly U.S.-produced, consistent with EO 13944 and the definition provided above. Please provide any additional information about your company s product or your company s understanding of the market conditions/availability of the product in general in the comments column. See the definitions tab of the spreadsheet for further information about each category.
Please also provide a response to the following:
Is your Company able to meet the following minimum requirements: National Drug Code (NDC): Offerors shall provide a separate and distinct eleven-digit NDC number unique to the offeror (e.g., 00012-3456-78) for each product proposed. The first five numbers of the eleven-digit NDC number (known as the labeler code) for each product proposed shall identify the offeror. Additionally, the successful offeror/contractor s label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Does your company have a unique NDC (Labeler Code)? _____________
If the offeror is not the manufacturer of the offered items, the offeror shall submit a letter of commitment from the manufacturer to the offeror which will assure the offeror a source of supply sufficient to satisfy the Government's requirements for the contract period. As noted, this may include that each offeror will maintain at least six months of stock for each awarded pharmaceutical.
Name of Manufacturer: _________________
Would you be able to provide a letter of commitment from the manufacturer for all pharmaceuticals that your company is interested in offering? _____________
Pharmaceutical Prime Vendor: All Ordering Activities under the Department of Veterans Affairs and Department of Defense acquire their pharmaceutical requirements through their Pharmaceutical Prime Vendor Program (PPV). The contractor shall ensure that chargeback agreements with the PPVs have been executed with sufficient time to permit the PPVs to begin timely distribution of Government orders, if an award is made. Does your company currently have a business-to-business agreement with the PPVs?_________
Under NAICS code 325412, is your company size (check one): Large Business ______ Small Business ______
If a small business, does your company manufacture (measure, weigh, mix, and compound) at least 50% of any or all of the products?_________
Please explain below what length of contract your company would be interested in. VA s goal is to establish a contract with a one-year base period plus four one-year option periods, which provide our customers with continuity and consistency of product by allowing long-term purchases of your product. _____________________________________________________________________
______________________________________________________________________
______________________________________________________________________



If an award were to be made based on the above requirements, would your company be able to begin supplying the product in the estimated quantities within 60 days of the contract award date? If not, please provide an estimated timeframe to prepare, providing any relevant details.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
If your company is uninterested or incapable in/of participating, please respond and provide as much background information possible. This aids our market research for future procurements.
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
Please provide your responses and completed spreadsheet to Diana.Martinez1@va.gov, Teresa.Hussain@va.gov, and Nicholas.McGregor@va.gov. If you could provide your responses to by next Thursday, June 24, 2026, it would be greatly appreciated. Please address all questions to the names noted above.
DISCLAIMER This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.

More opportunities from Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

Same awarding agency

NAICS: 325412
New
Federal
6505--Ticagrelor Tablets
Solicitation # 36E79726R0028
The Department of Veterans Affairs National Acquisition Center is seeking an unrestricted procurement to establish an uninterrupted source of supply for Ticagrelor Tablets. This firm-fixed-price, indefinite-delivery requirements contract supports multiple federal health agencies, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. The award is designated as a HUBZONE small business set-aside and will be granted to the lowest-priced, technically acceptable offeror. The contract structure consists of a base year and four one-year options, with a maximum 60-calendar day implementation period before the ordering period begins. The scope of work includes the supply of Ticagrelor in 60mg and 90mg strengths across various bottle sizes, ranging from 60 to 1,000 tablets. Strict packaging and labeling standards are required, including the use of cylindrical bottles with a minimum 120cc volume and 5.75 inch circumference, safety caps that are convertible or deshelled, and unique 11-digit NDC numbers. All products must be compatible with automated dispensing units and feature GS1-128 or HIBC linear bar codes, as well as two-dimensional data matrix bar codes per the Drug Supply Chain Security Act. To be eligible for award, offerors must maintain an acceptable FDA cGMP status for their manufacturing facilities and provide the necessary NDA, ANDA, or BLA clearances. Those who are not the manufacturer must provide a formal Letter of Commitment ensuring a sufficient source of supply. Distribution will be managed through Government Prime Vendor contracts, with deliveries made to approximately 56 VA and DoD distribution centers nationwide. Proposals must be submitted in PDF or Word format, including a signed SF-1449 and pricing for all line items across the base and option years, with prices held firm for 120 calendar days.
Pharmaceutical Preparation Manufacturing

POSTED

3 days ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
Federal
6505--2027-2028 Influenza Virus Vaccine
Solicitation # 36E79726R0035
Solicitation 36E79726R0035 is an unrestricted FAR Part 12 commercial-item procurement issued by the Department of Veterans Affairs National Acquisition Center for the supply of Influenza Virus Vaccines for the 2027-2028 season. The contract requires the delivery of trivalent or quadrivalent vaccines in pre-filled single-dose syringes with plunger and Luer lock needle attachments, provided in boxes of 10. The vaccines must be latex and preservative free, with specific FDA approval and labeling required for pediatric populations (6 to 35 months) and seniors (65 years and older). Final vaccine presentation is based on World Health Organization recommendations, with a preference for Trivalent presentations if both Trivalent and Quadrivalent options are commercially available. The award will be made on a per solicitation line item basis for the VA, Bureau of Prisons, Indian Health Service, and the Captain James A. Lovell Federal Health Care Center. Deliveries are Free On Board Destination to government facilities across the United States, Puerto Rico, and the Philippines. Most facilities require a two-part delivery schedule, with at least 50 percent of the order delivered between August 15 and September 15, 2027, and the remainder by October 15, 2027; however, the FHCC must receive 100 percent of its awarded quantity by September 15, 2027. Offerors must provide the full quantity for any line item bid, and final pricing must include the Cost Recovery Fee and Federal Excise Tax.
Pharmaceutical Preparation Manufacturing

POSTED

4 days ago

DEADLINE

in 11 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS